SalonHQ Competitors

Founded in 2018, Acrotech Biopharma Inc was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research based organization that strives to launch treatments which are accessible to patients that need them.

Parabiotic Research & Development Corp (Parabiotic) controls through its principal owner, three critical US patents (and four additional in foreign jurisdictions) that protect combinations of antibiotic and probiotic drugs encapsulated together as one single dose for the treatment of Inflammatory Bowel Disease (IBD) - ulcerative colitis and Crohn's disease - as well as Irritable Bowel Syndrome (IBS), traveler's diarrhea and other infectious diseases. Three decades ago, early research on this treatment regimen was abandoned by the pharmaceutical industry based on its decision to pursue very expensive alternate treatments, i.e., immunosuppressants, and biologics which can mask the symptoms, but do little to cure the underlying causes. Pre-FDA research on the combination of antibiotic and probiotic drugs was shelved as big Pharma saw profits for these alternative treatments explode in value. Full-circle now, and with new evidence for bacterial linkage as a causal factor for initiation in this disease is well documented by leading investigators worldwide, confirming a renewed impetus for developing Parabiotic's antibiotic/probiotic approach for treatment. The Company's patents protect the important combination aspects of this approach, and after many years of research, we understand the protocols necessary for a full recovery from these appalling diseases. Parabiotic is seeking a co-development partner to bring this combination of antibiotic and probiotic drugs to market, and to provide patients with a potentially curative treatment which will mitigate the debilitating adverse side effects of current treatments based on biologics and immunosuppressants. The Company has a wealth of research material, as well as the seven patents enabling a license partner to have an early advantage for multiple years on the market that will provide real relief to the 8 million sufferers of IBD worldwide, including IBS and other infectious diseases.

Pharmacotherapy Publications is a publishing company based out of 750 Washington St # 806, Boston, Massachusetts, United States.